Search
for
Sort by
Research 31–60 of 1000+
- There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses
- Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease
- Updated Integrated Safety Analysis of Ritlecitinib Up to ~5 Years in Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
- Machine Learning--Enhanced Pharmacovigilance Assessment of Cardiac Adverse Events Associated With Minoxidil
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark
- Polycystic Ovary Syndrome and Cardiovascular Disease: A Premature Association?
- Machine Learning–Enhanced Pharmacovigilance Assessment of Cardiac Adverse Events Associated with Minoxidil
- Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome
- Cardiovascular Toxicities of Androgen Deprivation Therapy
- Cardiovascular Risk Associated With Gender Affirming Hormone Therapy in Transgender Population
- Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome
- No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study
- A hospital-based study to assess the prevalence of Androgenetic alopecia in young male patients admitted to a Cardiac care unit (2021)
- LB1101 Evaluating the cardiovascular safety of low-dose oral minoxidil in patients with non-scarring alopecia: A retrospective cohort study
- Cardiovascular effects of hormone therapy for prostate cancer
- Cardiovascular risk markers in premature canities
- Low dose oral minoxidil and the conundrum of cardiovascular complications
- Effect of High Levels of Testosterone on Cardiovascular Risk in Polycystic Ovary Syndrome (PCOS)
- The Cardiovascular Safety of Dutasteride
- No increased risk of CV events with dutasteride vs finasteride
- Reporting on Adverse Clinical Events
- A Review of the Relationships Between Endogenous Sex Steroids and Incident Ischemic Stroke and Coronary Heart Disease Events
- PD49-03 IS TADALAFIL ASSOCIATED WITH DECREASED RISK OF MAJOR ADVERSE CARDIAC EVENTS OR VENOUS THROMBOEMBOLISM IN MEN WITH LOWER URINARY TRACT SYMPTOMS?
- Reporting on Adverse Clinical Events
- Medication Clusters at Hospital Discharge and Risk of Adverse Drug Events at 30-days Post-Discharge: A Population-based Cohort Study of Older Adults
- Estimation of biological heart age using cardiovascular magnetic resonance radiomics
- The Role of Patient‐ and Drug‐Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data From the United States Food and Drug Administration Adverse Event Reporting System